ADVOCATE. CONNECT. INNOVATE.

CLSA Wire

A Closer Look at FDA Drug Review Performance
Facebook
Twitter
LinkedIn

Biopharmaceutical innovation – new treatments for patients in need – depends on FDA processes that are rigorous, science-based, consistent, transparent and predictable. The Agency has made progress decreasing review times, however room for improvement remains. For example, review times vary across therapeutic areas, potentially influencing industry and investor resource decisions.

View Full Report